Login to Your Account

Clinic Roundup

Friday, June 28, 2013
• Access Pharmaceuticals Inc., of Dallas, said top-line results from a Phase IV study showed that Mugard mucoadhesive oral wound rinse met the primary study endpoint, with patients receiving the product experiencing a statistically significant reduction vs. placebo in mouth and throat soreness.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription